IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat.
Long term effects of in vivo treatment with human rIL-1 beta on diabetogenesis and thyroid disease were determined in the Biobreeding rat. Administration of high dose (10 micrograms/kg) IL-1 beta accelerated the onset of insulin-dependent diabetes mellitus compared to saline-injected controls. High dose treatment resulted in goiter development, pronounced LT, reduced serum T4 levels, and overall growth reduction. In contrast, low dose IL-1 beta (0.5 microgram/kg) administration significantly reduced the frequency of insulin-dependent diabetes mellitus (48%) compared to placebo (86%) and high dose IL-1 beta (93%) treatment groups. Rats protected by low dose IL-1 beta had unaffected growth rates and minimal to no pancreatic and thyroid pathology. Our results demonstrate that exogenous administration of IL-1 beta modulates Biobreeding rat idiopathic autoimmune diabetes and thyroid disease in a dose-dependent manner.
Wilson
C A
CA
Department of Medicine, University of Washington, Seattle 98195.
Jacobs
C
C
Baker
P
P
Baskin
D G
DG
Dower
S
S
Lernmark
A
A
Toivola
B
B
Vertrees
S
S
Wilson
D
D
D000818:Animals; D001835:Body Weight; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D007375:Interleukin-1 / Q000494:pharmacology / Q000502:physiology*; D007958:Leukocyte Count / Q000187:drug effects; D009929:Organ Size; D051381:Rats; D011922:Rats, Mutant Strains / Q000276:immunology; D011994:Recombinant Proteins; D013967:Thyroiditis, Autoimmune / Q000503:physiopathology*
D007375:Interleukin-1; D011994:Recombinant Proteins